Acadia Pharmaceuticals | ACAD - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 27.55M 1.63M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
Cara Therapeutics -89.64M 128.67M 2025-12
Corcept Therapeutics USD 1.03B 145.32M 2026-09
Cytokinetics USD 38.48M 3.65M 2026-09
Eisai JPY 2.18B 220M 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Incyte USD 605K 23K 2026-09
J&J USD 43M 25M 2026-03
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 300K 2.6M 2026-09
Pfizer USD 662M 5M 2026-09
Prothena USD 283.52M 19.06M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 36M 32.7M 2026-09